maradonna 8888 / Shutterstock.com
The English Court of Appeal has issued the latest ruling in the patent dispute between Warner-Lambert and Actavis concerning Lyrica (pregabalin), says Arty Rajendra of Rouse Legal.
At 10:30am on June 29, a London court room packed full of patent lawyers will fall silent as the trial in Warner-Lambert v Actavis commences.
This case has already attracted significant media attention because it will determine how generic manufacturers market drugs for which the primary patent protection has expired but a second medical use patent for the drug remains valid.
Warner-Lambert, owned by pharmaceutical company Pfizer, markets the drug pregabalin under the brand name Lyrica.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Warner-Lambert, Actavis, patent, patent infringement, medical use, pregabalin,